{"id":31907,"date":"2025-04-16T15:08:00","date_gmt":"2025-04-16T07:08:00","guid":{"rendered":"https:\/\/flcube.com\/?p=31907"},"modified":"2025-04-16T15:08:01","modified_gmt":"2025-04-16T07:08:01","slug":"innocare-pharmas-zurletrectinib-nda-accepted-by-chinas-cde-for-trk-fusion-cancers","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=31907","title":{"rendered":"InnoCare Pharma’s Zurletrectinib NDA Accepted by China’s CDE for TRK Fusion Cancers"},"content":{"rendered":"\n

Beijing-based biopharmaceutical company InnoCare Pharma (HKG: 9969<\/a>, SHA: 688428<\/a>) has announced that China\u2019s Center for Drug Evaluation (CDE) has accepted the New Drug Application (NDA) for its next-generation pan-TRK inhibitor zurletrectinib (ICP-723). The proposed indication targets adult and adolescent patients (aged 12\u201318) with advanced solid tumors harboring NTRK gene fusions.<\/p>\n\n\n\n

Zurletrectinib: Mechanism and Efficacy<\/strong>
Zurletrectinib is a Category 1 drug designed to treat advanced or metastatic solid tumors with NTRK gene fusions, including those resistant to first-generation TRK inhibitors. Preclinical studies demonstrated outstanding efficacy and a favorable safety profile, positioning it as a promising therapeutic option for patients with limited treatment choices.<\/p>\n\n\n\n

Clinical and Market Implications<\/strong>
NTRK gene fusions occur in various adult and pediatric tumors, with high incidence rates observed in rare cancers such as salivary gland carcinoma, secretory breast cancer, and infantile fibrosarcoma (exceeding 90% in some cases). The acceptance of the NDA by the CDE marks a significant step toward making zurletrectinib available to patients in China, potentially addressing critical unmet medical needs.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Beijing-based biopharmaceutical company InnoCare Pharma (HKG: 9969, SHA: 688428) has announced that China\u2019s Center for…<\/p>\n","protected":false},"author":1,"featured_media":31908,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[919,327,38,920],"class_list":["post-31907","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-hkg-9969","tag-innocare-pharma","tag-market-approval-filings","tag-sha-688428"],"yoast_head":"\nInnoCare Pharma's Zurletrectinib NDA Accepted by China's CDE for TRK Fusion Cancers - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Beijing-based biopharmaceutical company InnoCare Pharma (HKG: 9969, SHA: 688428) has announced that China\u2019s Center for Drug Evaluation (CDE) has accepted the New Drug Application (NDA) for its next-generation pan-TRK inhibitor zurletrectinib (ICP-723). The proposed indication targets adult and adolescent patients (aged 12\u201318) with advanced solid tumors harboring NTRK gene fusions.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=31907\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"InnoCare Pharma's Zurletrectinib NDA Accepted by China's CDE for TRK Fusion Cancers\" \/>\n<meta property=\"og:description\" content=\"Beijing-based biopharmaceutical company InnoCare Pharma (HKG: 9969, SHA: 688428) has announced that China\u2019s Center for Drug Evaluation (CDE) has accepted the New Drug Application (NDA) for its next-generation pan-TRK inhibitor zurletrectinib (ICP-723). The proposed indication targets adult and adolescent patients (aged 12\u201318) with advanced solid tumors harboring NTRK gene fusions.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=31907\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-16T07:08:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-04-16T07:08:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1608.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31907#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31907\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"InnoCare Pharma’s Zurletrectinib NDA Accepted by China’s CDE for TRK Fusion Cancers\",\"datePublished\":\"2025-04-16T07:08:00+00:00\",\"dateModified\":\"2025-04-16T07:08:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31907\"},\"wordCount\":180,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31907#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/1608.webp\",\"keywords\":[\"HKG: 9969\",\"InnoCare Pharma\",\"Market approval filings\",\"SHA: 688428\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=31907#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31907\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=31907\",\"name\":\"InnoCare Pharma's Zurletrectinib NDA Accepted by China's CDE for TRK Fusion Cancers - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31907#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31907#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/1608.webp\",\"datePublished\":\"2025-04-16T07:08:00+00:00\",\"dateModified\":\"2025-04-16T07:08:01+00:00\",\"description\":\"Beijing-based biopharmaceutical company InnoCare Pharma (HKG: 9969, SHA: 688428) has announced that China\u2019s Center for Drug Evaluation (CDE) has accepted the New Drug Application (NDA) for its next-generation pan-TRK inhibitor zurletrectinib (ICP-723). The proposed indication targets adult and adolescent patients (aged 12\u201318) with advanced solid tumors harboring NTRK gene fusions.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31907#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=31907\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31907#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/1608.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/1608.webp\",\"width\":1080,\"height\":608,\"caption\":\"InnoCare Pharma's Zurletrectinib NDA Accepted by China's CDE for TRK Fusion Cancers\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31907#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"InnoCare Pharma’s Zurletrectinib NDA Accepted by China’s CDE for TRK Fusion Cancers\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"InnoCare Pharma's Zurletrectinib NDA Accepted by China's CDE for TRK Fusion Cancers - Insight, China's Pharmaceutical Industry","description":"Beijing-based biopharmaceutical company InnoCare Pharma (HKG: 9969, SHA: 688428) has announced that China\u2019s Center for Drug Evaluation (CDE) has accepted the New Drug Application (NDA) for its next-generation pan-TRK inhibitor zurletrectinib (ICP-723). The proposed indication targets adult and adolescent patients (aged 12\u201318) with advanced solid tumors harboring NTRK gene fusions.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=31907","og_locale":"en_US","og_type":"article","og_title":"InnoCare Pharma's Zurletrectinib NDA Accepted by China's CDE for TRK Fusion Cancers","og_description":"Beijing-based biopharmaceutical company InnoCare Pharma (HKG: 9969, SHA: 688428) has announced that China\u2019s Center for Drug Evaluation (CDE) has accepted the New Drug Application (NDA) for its next-generation pan-TRK inhibitor zurletrectinib (ICP-723). The proposed indication targets adult and adolescent patients (aged 12\u201318) with advanced solid tumors harboring NTRK gene fusions.","og_url":"https:\/\/flcube.com\/?p=31907","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-04-16T07:08:00+00:00","article_modified_time":"2025-04-16T07:08:01+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1608.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=31907#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=31907"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"InnoCare Pharma’s Zurletrectinib NDA Accepted by China’s CDE for TRK Fusion Cancers","datePublished":"2025-04-16T07:08:00+00:00","dateModified":"2025-04-16T07:08:01+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=31907"},"wordCount":180,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=31907#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1608.webp","keywords":["HKG: 9969","InnoCare Pharma","Market approval filings","SHA: 688428"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=31907#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=31907","url":"https:\/\/flcube.com\/?p=31907","name":"InnoCare Pharma's Zurletrectinib NDA Accepted by China's CDE for TRK Fusion Cancers - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=31907#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=31907#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1608.webp","datePublished":"2025-04-16T07:08:00+00:00","dateModified":"2025-04-16T07:08:01+00:00","description":"Beijing-based biopharmaceutical company InnoCare Pharma (HKG: 9969, SHA: 688428) has announced that China\u2019s Center for Drug Evaluation (CDE) has accepted the New Drug Application (NDA) for its next-generation pan-TRK inhibitor zurletrectinib (ICP-723). The proposed indication targets adult and adolescent patients (aged 12\u201318) with advanced solid tumors harboring NTRK gene fusions.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=31907#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=31907"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=31907#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1608.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1608.webp","width":1080,"height":608,"caption":"InnoCare Pharma's Zurletrectinib NDA Accepted by China's CDE for TRK Fusion Cancers"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=31907#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"InnoCare Pharma’s Zurletrectinib NDA Accepted by China’s CDE for TRK Fusion Cancers"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1608.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/31907","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=31907"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/31907\/revisions"}],"predecessor-version":[{"id":31909,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/31907\/revisions\/31909"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/31908"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=31907"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=31907"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=31907"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}